DK0574313T3 - 1,4-disubstituerede piperaziner til behandling af sygdomme i centralnervesystemet og neuroendocrine sygdomme - Google Patents

1,4-disubstituerede piperaziner til behandling af sygdomme i centralnervesystemet og neuroendocrine sygdomme

Info

Publication number
DK0574313T3
DK0574313T3 DK93401476T DK93401476T DK0574313T3 DK 0574313 T3 DK0574313 T3 DK 0574313T3 DK 93401476 T DK93401476 T DK 93401476T DK 93401476 T DK93401476 T DK 93401476T DK 0574313 T3 DK0574313 T3 DK 0574313T3
Authority
DK
Denmark
Prior art keywords
treatment
nervous system
central nervous
disubstituted piperazines
neuroendocrine disorders
Prior art date
Application number
DK93401476T
Other languages
English (en)
Inventor
Jean-Louis Peglion
Bertrand Goument
Mark Millan
Jean-Michel Rivet
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adir filed Critical Adir
Application granted granted Critical
Publication of DK0574313T3 publication Critical patent/DK0574313T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
DK93401476T 1992-06-12 1993-06-10 1,4-disubstituerede piperaziner til behandling af sygdomme i centralnervesystemet og neuroendocrine sygdomme DK0574313T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR929207065A FR2692264B1 (fr) 1992-06-12 1992-06-12 Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.

Publications (1)

Publication Number Publication Date
DK0574313T3 true DK0574313T3 (da) 2000-04-03

Family

ID=9430639

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93401476T DK0574313T3 (da) 1992-06-12 1993-06-10 1,4-disubstituerede piperaziner til behandling af sygdomme i centralnervesystemet og neuroendocrine sygdomme

Country Status (13)

Country Link
US (1) US5464834A (da)
EP (1) EP0574313B1 (da)
JP (1) JP2634370B2 (da)
AT (1) ATE185345T1 (da)
AU (1) AU658512B2 (da)
CA (1) CA2098252A1 (da)
DE (1) DE69326637T2 (da)
DK (1) DK0574313T3 (da)
ES (1) ES2139638T3 (da)
FR (1) FR2692264B1 (da)
GR (1) GR3031492T3 (da)
NZ (1) NZ247854A (da)
ZA (1) ZA934143B (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9125900D0 (en) * 1991-12-05 1992-02-05 Wyeth John & Brother Ltd Piperazine derivatives
GB9308725D0 (en) * 1993-04-27 1993-06-09 Wyeth John & Brother Ltd Piperazine derivatives
FR2734819B1 (fr) * 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
US6156057A (en) * 1995-08-12 2000-12-05 Fox; James Allan Method for inducing hypothermia
JPH09124643A (ja) * 1995-08-14 1997-05-13 Bristol Myers Squibb Co 抗うつ作用を有する１−アリールアルキル−４−（アルコキシピリジニル）−又は４−（アルコキシピリミジニル）ピペラジン誘導体
FR2738823B1 (fr) * 1995-09-15 1997-10-31 Synthelabo Derives de 3-(omega-(4-(thieno(3,2-c)pyridin-4-yl)piperazin- 1-yl)alkyl)-3,4-dihydroquinolein-2(1h)-one,leur preparation et leur application en therapeutique
US5990114A (en) * 1996-02-28 1999-11-23 Recordati, S.A., Chemical And Pharmaceutical Company Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence
US6090132A (en) * 1996-08-15 2000-07-18 Fox; James Allan Method and apparatus for inducing hypothermia
ES2205267T3 (es) * 1996-12-20 2004-05-01 H. Lundbeck A/S Derivados de indano o de dihidroindol.
US6436940B2 (en) 1996-12-20 2002-08-20 H. Lundbeck A/S Indane or dihydroindole derivatives
FR2761358B1 (fr) * 1997-03-27 1999-05-07 Adir Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ES2128266B1 (es) 1997-07-08 2000-01-16 Vita Invest Sa Compuestos derivados de tiofeno y benzotiofeno y utilizacion y composicion correspondientes.
KR100545329B1 (ko) 1997-07-25 2006-01-24 하. 룬트벡 아크티에 셀스카브 인돌 및 2,3-디히드로인돌 유도체, 그들의 제조방법 및 사용
AR013206A1 (es) * 1997-07-25 2000-12-13 Lundbeck & Co As H Derivados indol y 2,3-dihidroindol, composiciones farmaceuticas que contienen estos compuestos y el uso de dichos compuestos para la preparacion de un medicamento para el tratamiento de desordenes sensibles a la inhibicion de la reabsorcion de serotonina y antagonismo de receptores 5-ht1a.
TW530054B (en) * 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
FR2769312B1 (fr) * 1997-10-03 1999-12-03 Adir Nouveaux composes de l'indanol, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN1191248C (zh) * 1997-10-24 2005-03-02 纽罗根公司 作为多巴胺d 受体亚型配体的1－(2－萘基)和1－(2－氮杂萘基)－4－(1－苯基甲基)哌嗪
US6040448A (en) 1997-10-24 2000-03-21 Neurogen Corporation Certain 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl) piperazines, dopamine receptor subtype specific ligands
US6177566B1 (en) 1998-06-30 2001-01-23 Neurogen Corporation 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(4-arylalkylpiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands
AR022303A1 (es) * 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
DE60013751T2 (de) * 1999-12-29 2005-09-29 Pfizer Products Inc., Groton Optisch aktive 3-((2-piperazinyl-phenyl)methyl)-1-(4-(trifluoromethyl)-phenyl)-2-pyrrolidinone als selektive 5-HT1D Rezeptor Antagonisten
ES2188344B1 (es) * 2000-11-29 2004-09-16 Laboratorios Vita, S.A. Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos.
ES2323451T7 (es) 2001-07-20 2011-08-01 Psychogenics Inc. Tratamiento para el trastorno de hiperactividad con deficit de atencion.
US20060122177A1 (en) * 2004-12-07 2006-06-08 Solvay Pharmaceuticals B.V. Phenylpiperazines with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
US7371769B2 (en) * 2004-12-07 2008-05-13 Solvay Pharmaceuticals B.V. Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
KR20070085988A (ko) * 2004-12-08 2007-08-27 솔베이 파마슈티칼스 비. 브이 부분 도파민-ｄ2 수용체 작용성과 세로토닌 재흡수억제성이 조합된 페닐피페라진 유도체
US8101619B2 (en) * 2004-12-08 2012-01-24 Solvay Pharmaceuticals B.V. Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition
FR2884251B1 (fr) * 2005-04-08 2007-07-13 Servier Lab Derives de piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2909670B1 (fr) 2006-12-12 2010-07-30 Sanofi Aventis Derive fluore de quinoleine-2(1h)-one,son procede de preparation et son utilisation comme intermediaire de synthese
SG10201510665WA (en) 2009-12-04 2016-01-28 Sunovion Pharmaceuticals Inc Multicycle Compounds And Pharmaceutical Compositions Useful For The Treatment Of Neurological Disorders
MA45795A (fr) 2016-07-29 2019-06-05 Sunovion Pharmaceuticals Inc Composés et compositions, et utilisations associées
PT3494119T (pt) 2016-07-29 2024-12-10 Pgi Drug Discovery Llc Compostos e composições e seus usos
MX390141B (es) 2017-02-16 2025-03-20 Sunovion Pharmaceuticals Inc Metodos para tratar esquizofrenia
CA3070993C (en) 2017-08-02 2025-05-20 Sunovion Pharmaceuticals Inc. ISOCHROMANE COMPOUNDS AND THEIR USES
WO2019029802A1 (en) * 2017-08-09 2019-02-14 Telefonaktiebolaget Lm Ericsson (Publ) SYSTEM AND METHOD FOR SELECTING ANTENNA BEAM
UA130249C2 (uk) 2018-02-16 2025-12-31 Сумітомо Фарма Америка, Інк. Солі, кристалічні форми і способи їх отримання
EP3938045A1 (en) 2019-03-14 2022-01-19 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
CA3180115A1 (en) 2020-04-14 2021-10-21 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders
CN113896709B (zh) * 2021-11-22 2023-02-28 南京一苇医药科技有限公司 一种苯并噻吩-3-乙酸的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2037852C3 (de) * 1970-07-30 1980-06-26 Boehringer Sohn Ingelheim Neue Piperazinderivate und Verfahren zu ihrer Herstellung
US4335126A (en) * 1977-03-10 1982-06-15 Degussa Aktiengesellschaft 1-[3-(3,4,5-Trimethoxyphenoxy)-2-hydroxy-propyl]-4-aryl-piperazine-derivatives having pharmaceutical activity
FR2515647A1 (fr) * 1981-11-03 1983-05-06 Cortial Nouvelles imines derivees de (phenyl-4 piperazinylethyl)-2 anilines, leur methode de preparation et leur application therapeutique
EP0190472B1 (en) * 1984-12-21 1989-07-12 Duphar International Research B.V New pharmaceutical compositions having anti-psychotic properties
DE3782525T2 (de) * 1986-02-27 1993-05-27 Duphar Int Res Aryl-substituierte(n-piperidinyl)methyl und (n-piperazinyl)methylazole mit antipsychotischer wirkung.
JPH01113377A (ja) * 1987-10-23 1989-05-02 Yoshitomi Pharmaceut Ind Ltd ピペラジン化合物
GB8830312D0 (en) * 1988-12-28 1989-02-22 Lundbeck & Co As H Heterocyclic compounds
FR2670491B1 (fr) * 1990-12-14 1993-02-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les renfermant.
DE4127849A1 (de) * 1991-08-22 1993-02-25 Merck Patent Gmbh Benzodioxanderivate

Also Published As

Publication number Publication date
CA2098252A1 (fr) 1993-12-13
AU658512B2 (en) 1995-04-13
GR3031492T3 (en) 2000-01-31
FR2692264A1 (fr) 1993-12-17
FR2692264B1 (fr) 1994-08-05
AU4017893A (en) 1993-12-16
ES2139638T3 (es) 2000-02-16
EP0574313A1 (fr) 1993-12-15
ATE185345T1 (de) 1999-10-15
JPH06179670A (ja) 1994-06-28
EP0574313B1 (fr) 1999-10-06
NZ247854A (en) 1994-09-27
JP2634370B2 (ja) 1997-07-23
ZA934143B (en) 1994-01-17
US5464834A (en) 1995-11-07
DE69326637T2 (de) 2000-05-18
DE69326637D1 (de) 1999-11-11

Similar Documents

Publication Publication Date Title
DK0574313T3 (da) 1,4-disubstituerede piperaziner til behandling af sygdomme i centralnervesystemet og neuroendocrine sygdomme
ATE125537T1 (de) 1,4-disubstituierte piperazine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen.
UA27749C2 (uk) Заміщені циклопропіламіно-1,3,5-триазини, їх оптичні ізомери, рацемічні суміші чи їх солі приєднання нетоксичних фармацевтично прийнятних кислот, що мають фармакологічну активність, спосіб їх одержання (варіанти) та фармацевтична композиція на їх основі
ATE116317T1 (de) Chinuclidinderivate.
FI961809A0 (fi) Uudet (R)-5-karbamoyyli-8-fluori-3-N,N-disubstituoitu-amino 3,4-dihydro-2H-1-bentsopyraanit
DK164937C (da) Analogifremgangsmaade til fremstilling af 1-alkyl-2-aminotetralinderivater eller farmaceutisk acceptable syreadditionssalte deraf samt 1-alkyl-2-aminotetralinderivater til anvendelse som udgangsmateriale i fremgangsmaaden
NO180632C (no) 1,3-substituerte cykloalkener og cykloalkaner som sentralnervesystem-midler
ATE147071T1 (de) 1,4-disubstituierte piperidinderivate, ihre herstellung und therapeutische verwendung
ATE122042T1 (de) Pyrazoloisoquinoline-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
PT783495E (pt) Derivados de quinoxalina uteis em terapia
DE69414194D1 (de) Aminosäurederivate und ihre Verwendung als Enkephalinase-Inhibitoren
ATE123776T1 (de) Aminoalkylchromone, verfahren zu ihrer herstellung und diese enthaltende zusammensetzungen.
ATE56705T1 (de) Piperidinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
DK0518769T3 (da) Hidtil ukendte ethanolaminbenzoatderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem.
ATE33493T1 (de) Phenylethylaminopropiophenon-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
ATE138805T1 (de) Substituiertes benzofuranylpiperidin als nootropikum
DE69320542D1 (de) Pyrrolothienopyrazin-Verbindungen als 5HT3-Rezeptoren-Antagonisten